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infection in the UK: a prospective national cohort study 
using active surveillance
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Summary
Background Babies differ from older children with regard to their exposure to severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). However, data describing the effect of SARS-CoV-2 in this group are scarce, and guidance 
is variable. We aimed to describe the incidence, characteristics, transmission, and outcomes of SARS-CoV-2 infection 
in neonates who received inpatient hospital care in the UK.
Methods We carried out a prospective UK population-based cohort study of babies with confirmed SARS-CoV-2 
infection in the first 28 days of life who received inpatient care between March 1 and April 30, 2020. Infected babies 
were identified through active national surveillance via the British Paediatric Surveillance Unit, with linkage to 
national testing, paediatric intensive care audit, and obstetric surveillance data. Outcomes included incidence (per 
10 000 livebirths) of confirmed SARS-CoV-2 infection and severe disease, proportions of babies with suspected 
vertically and nosocomially acquired infection, and clinical outcomes.
Findings We identified 66 babies with confirmed SARS-CoV-2 infection (incidence 5·6 [95% CI 4·3–7·1] per 
10 000 livebirths), of whom 28 (42%) had severe neonatal SARS-CoV-2 infection (incidence 2·4 [1·6–3·4] per 
10 000 livebirths). 16 (24%) of these babies were born preterm. 36 (55%) babies were from white ethnic groups (SARS-
CoV-2 infection incidence 4·6 [3·2–6·4] per 10 000 livebirths), 14 (21%) were from Asian ethnic groups (15·2 [8·3–25·5] 
per 10 000 livebirths), eight (12%) were from Black ethnic groups (18·0 [7·8–35·5] per 10 000 livebirths), and seven 
(11%) were from mixed or other ethnic groups (5·6 [2·2–11·5] per 10 000 livebirths). 17 (26%) babies with confirmed 
infection were born to mothers with known perinatal SARS-CoV-2 infection, two (3%) were considered to have possible 
vertically acquired infection (SARS-CoV-2-positive sample within 12 h of birth where the mother was also positive). 
Eight (12%) babies had suspected nosocomially acquired infection. As of July 28, 2020, 58 (88%) babies had been 
discharged home, seven (11%) were still admitted, and one (2%) had died of a cause unrelated to SARS-CoV-2 infection.
Interpretation Neonatal SARS-CoV-2 infection is uncommon in babies admitted to hospital. Infection with neonatal 
admission following birth to a mother with perinatal SARS-CoV-2 infection was unlikely, and possible vertical 
transmission rare, supporting international guidance to avoid separation of mother and baby. The high proportion of 
babies from Black, Asian, or minority ethnic groups requires investigation.
Funding UK National Institute for Health Research Policy Research Programme.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Children appear to be less severely affected by severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) than adults.1 However, there is a paucity of data 
describing the effect of the virus on babies in the first 
28 days after birth. Neonates are likely to differ from 
older groups in their exposure to the virus: although 
they can contract SARS-CoV-2 through close personal 
contact in much the same way as other groups, they 
might also contract the virus vertically before or at 
birth.2 The neonatal response to infection differs from 
that of older children and adults,3 and hence neonates 
might be more susceptible to infection or to severe 
disease.
The scarce data available suggest that severe disease 
might be more common in infants4 and neonates5 than 
in older children. However, these data are largely from 
case reports and series and, to the best of our knowledge, 
are not population-based. Consequently, the incidence of 
symptomatic neonatal SARS-CoV-2 infection and vertical 
transmission, features of presentation, severity, and 
outcomes at the population level are unknown.
The paucity of information about neonatal disease and 
concerns about SARS-CoV-2 transmission from mother to 
newborn6 have resulted in wide variation in guidance for 
the management of neonates at risk of SARS-CoV-2.7 In 
some countries, such as China, the immediate, routine 
separation of newborn infants from SARS-CoV-2-infected 
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mothers is recommended, with no breastfeeding.7 By 
contrast, WHO recommendations8 and UK guidance9 
support keeping mother and baby together and 
encouraging breast feeding with hygiene precautions. 
Separating a mother and her newborn baby is likely 
to have deleterious consequences for mother–infant 
bonding, perinatal mental health,10 and breast feeding.11 It 
is therefore crucial that, with the emergence of new 
diseases, policy is guided by robust and unbiased data.
The aim of this study was to describe, on a population 
basis, the incidence, characteristics, transmission, and 
outcomes of SARS-CoV-2 infection in babies who 
received inpatient hospital care in the UK in the first 
28 days after birth, in order to inform policy, ongoing 
management, and guidance for health-care professionals, 
pregnant women, and new parents.
Methods
Study design and procedures 
A national prospective cohort study was carried out 
using the British Paediatric Surveillance Unit (BPSU).12 
Established in 1985, the BPSU is a surveillance platform 
designed to carry out national studies of rare neonatal 
and paediatric diseases. From April 1, 2020, all 
consultant paediatricians in all 155 hospital trusts and 
health boards with their associated 190 neonatal units in 
the UK received a weekly electronic BPSU reporting 
card asking them to notify any eligible cases of 
neonatal SARS-CoV-2 infection diagnosed on or after 
March 1, 2020. Babies were eligible for inclusion if they 
had a diagnosis of SARS-CoV-2 infection made on a 
sample taken in the first 28 days after birth and received 
inpatient care on a postnatal ward, neonatal unit, 
paediatric inpatient ward, or paediatric intensive care 
unit (PICU). At the end of each month, an additional 
BPSU reporting card asked for confirmation that all 
eligible babies had been reported or to confirm zero 
reports for the month (active negative surveillance). 
During the study period, national policy did not 
recommend routine testing of neonates for SARS-CoV-2 
in any clinical setting.
To maximise case ascertainment, data from 
Public Health England, Health Protection Scotland, the 
Paediatric Intensive Care Audit Network (PICANet),13 and 
Research in context
Evidence before this study
This study was developed and initiated at the outset of the 
COVID-19 pandemic in the UK in March, 2020. At inception we 
searched PubMed and the preprint server MedRxiv using the 
terms “neonate”, “neonatal”, “SARS-CoV-2”, and “COVID-19”, 
from Jan 1, 2020, and without language limitations, for papers 
describing the incidence, presentation, and outcomes of 
neonatal severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection. This search identified a single national 
population-based study of 2143 children with confirmed or 
suspected SARS-CoV-2 infection in China, in which the authors 
had developed a disease severity grading for children, and 
found that infants in the first year of life might have more 
severe disease compared with older children. Case reports and 
series were identified from China indicating possible vertical 
transmission of SARS-CoV-2 from mother to newborn baby.
A search was repeated using the same search terms and 
databases on July 28, 2020, with an additional search of the 
relevant Johns Hopkins Center for Humanitarian Health 
repository (COVID-19, Maternal and Child Health, Nutrition) 
using the search terms “neonate” and “neonatal”. Proposed 
criteria for vertical transmission of SARS-CoV-2 had been 
published, as well as further detailed case reports describing 
babies in whom vertical transmission was highly suggested. 
We found one systematic review of births following maternal 
SARS-CoV-2 infection, which included numerous case reports, 
single-centre case series, voluntary registries (at high risk of 
bias), and a single population-level study from the UK Obstetric 
Surveillance System that used active national surveillance. 
This UK-based study described 12 babies with SARS-CoV-2 
following birth to mothers with confirmed infection, but did 
not describe clinical presentation or detailed information about 
diagnosis. A European multicentre voluntary registry study of 
paediatric SARS-CoV-2 infection reported 40 babies across 
84 institutions, and a national cohort study of children with 
SARS-CoV-2 infection in the UK reported 53 babies. These 
studies described presentation, clinical course, and outcome 
across all paediatric groups, with little neonatal data, and were 
not sufficient to inform population-level incidence because of 
uncertainty about the completeness of case ascertainment and 
population coverage. We also identified guideline reviews 
showing that guidance for the management of babies born to 
women with confirmed or suspected SARS-CoV-2 infection 
varied between countries, with routine separation of mother 
and baby advised in many countries.
Added value of this study
Our study is the first national, active surveillance study of 
neonatal SARS-CoV-2 infection. We found that SARS-CoV-2 
infection was uncommon among neonates receiving inpatient 
care, with only 66 cases identified in the UK between March and 
April, 2020. Most babies were mildly affected, with cases of 
severe disease being very rare. Infection requiring admission to 
a neonatal care unit following birth to a mother with perinatal 
SARS-CoV-2 infection was uncommon, with only 17 cases 
identified across the UK during the study period, and only two 
babies with possible vertical transmission were identified in the 
UK during the first peak of SARS-CoV-2 transmission.
Implications of all the available evidence
This study supports international guidance to avoid separation 
of mother and baby after birth in situations in which the 
mother has suspected or confirmed SARS-CoV-2 infection.
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the UK Obstetric Surveillance System (UKOSS)14 were 
used to identify any baby with a positive SARS-CoV-2 test 
taken in the first 28 days not reported through the BPSU. 
Following linkage, newly identified cases from these 
sources were followed up through local BPSU reporters 
and research nurses. Where cases identified through 
national testing data were unable to be matched to 
hospital records at the site of the test, they were 
categorised as not admitted for inpatient care and 
therefore excluded from the study. Deaths were verified 
with data from the MBRRACE-UK national surveillance 
of perinatal deaths.15
Following receipt of a report, notifying clinicians were 
asked to complete a data collection form (appendix 1) with 
details of the pregnancy, baby characteristics, neonatal 
management, and outcomes. Reporters who had not 
returned the form were contacted by email at 1, 2, and 
4 weeks after notification. Data collection was supported by 
hospital-based research nurses from the UK’s National 
Institute of Health Research (NIHR) Clinical Research 
Network following the study’s adoption as an urgent public 
health priority study.
Parents, patients, and the public were consulted 
during the design of the study through the MBRRACE-
UK third-sector stakeholder group, which comprises 
represen tatives from all the major mother and baby 
charities in the UK. The study protocol is available 
online.
The study was approved by the North East—Newcastle 
& North Tyneside 2 Research Ethics Committee (IRAS 
ID 282127; REC 20/NE/0107). Data were collected in 
England and Wales without parental consent following 
Section 251 advice from the Confidentiality Advisory 
Group of the Health Research Authority (20/CAG/0058) 
and under the COVID-19 notice issued by the Secretary 
of State for Health and Social Care under Regulation 3(4) 
of the Health Service Control of Patient Information 
Regulations 2002. Data were collected in Scotland 
without parental consent following COVID-19 rapid 
review and advice from the Public Benefit and Privacy 
Panel for Health and Social Care (1920-0288), and with 
maternal consent following advice from the Privacy 
Commissioner in Northern Ireland.
Outcomes and definitions
This analysis presents characteristics and outcomes 
for babies reported as having confirmed SARS-CoV-2 
infection before 29 days of age between March 1 and 
April 30, 2020, and for whom complete data had been 
received by July 28, 2020.
For the purpose of this study, severe disease included 
both severe and critical disease, defined according to 
Dong and colleagues’ criteria,4 which required that cases 
meet at least two of the following: (1) any of hyper thermia 
(>37·5°C), apnoea, cough, tachypnoea, respiratory distr-
ess or recession, supplemental oxygen requirement, poor 
feeding or vomiting, or diarrhoea; (2) any of low white 
blood cell count (<5 × 10⁹/L), low lymphocyte count 
(<1 × 10⁹/L), or raised C-reactive protein concentration 
(>5 mg/L); and (3) abnormal chest x-ray.
Possible vertically acquired infection was defined as a 
positive neonatal sample taken within the first 12 h 
following birth to a mother with confirmed SARS-CoV-2 
infection; this definition is consistent with UKOSS 
criteria14 and with the criteria for probable or possible 
neonatal infection acquired intrapartum as defined by 
Shah and colleagues.16
Statistical analysis
Descriptive statistics are presented as frequencies, 
proportions, means, and standard deviations as appro-
priate. The incidence and 95% CIs of babies in hospital 
with confirmed SARS-CoV-2 infection were estimated 
using denominator estimates of total UK livebirths based 
on the most recently available (2018) complete national 
birth data for the four countries of the UK. Incidence 
according to gestational age at birth and ethnicity was 
also estimated using denominator estimates of livebirths 
in England and Wales in 2018.
The study is registered with ISRCTN (ISRCTN60033461).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Monthly BPSU card returns were received from 
3530 (87%) of 4063 UK paediatricians in March and 
3480 (85%) of 4084 in April, 2020. 66 potentially eligible 
neonates were reported to the BPSU system over the 
study period and 23 additional babies were identified from 
other sources (figure 1).
66 neonates with SARS-CoV-2 infection diagnosed 
between March 1 and April 30, 2020, received inpatient 
care in the UK. Over the same period, there were an 
estimated 118 347 livebirths, giving a neonatal incidence 
of SARS-CoV-2 infection of 5·6 (95% CI 4·3–7·1) per 
10 000 livebirths. The England-specific incidence was 
6·4 (4·9–8·2) per 10 000 livebirths. 28 babies in the UK 
met the criteria for severe paediatric SARS-CoV-2 
infection4 (incidence 2·4 [1·6–3·4] per 10 000 births; 
table 1). Neonatal diagnoses peaked in early April 
(figure 2). The median age of diagnosis was 9·5 days 
(IQR 7·5–11·0) and 45 (68%) babies were diagnosed 
more than 7 days after birth (figure 2).
17 (26%) babies with SARS-CoV-2 infection were born 
to a mother who had confirmed infection within 7 days 
before or after birth (table 2). Two of these babies 
(including one identified by UKOSS) had SARS-CoV-2 
detected on a nasopharyngeal swab taken within 12 h of 
birth and were therefore deemed to have a possible 
For the study protocol see 
www.npeu.ox.ac.uk/pru-mnhc/
research-themes/theme-4/
covid-19
See Online for appendix 1
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vertically acquired infection; both had no further 
SARS-CoV-2 testing. UKOSS14 previously identified 
six babies as having possible vertically acquired infection 
using the same criterion (positive test taken within 12 h 
of birth to a mother with SARS-CoV-2 infection). These 
six cases were included in our study via database linkage, 
but further follow-up found that five of these cases were 
false positives; therefore, our final cohort only included 
one of these six babies, who had confirmed SARS-CoV-2 
infection identified from a sample taken in the first 12 h 
after birth. Eight (47%) of the 17 cases in which both 
baby and mother had confirmed SARS-CoV-2 infection 
(including one baby with possible vertically acquired 
infection) had remained with their mother after birth. 
Seven (41%) had been separated immediately after birth, 
of whom three (including one preterm baby with possible 
vertically acquired infection) were admitted to a neonatal 
care unit. Where babies remained with their mother, the 
mother was advised regarding hand washing (to wash 
hands before touching the baby, breast pump, or bottles) 
and to wear a fluid-resistant surgical mask while handling 
the baby, and breastfeeding was recommended.9
21 (32%) babies were diagnosed with SARS-CoV-2 
infection in the first 7 days after birth, including 14 babies 
born to a mother with confirmed infection. Overall, 
34 (52%) babies had immediate family or close contacts 
with signs or symptoms consistent with SARS-CoV-2 
infection. Eight (12%) babies were suspected to have 
SARS-CoV-2 infection from nosocomial transmission 
and were not born to a mother with confirmed SARS-
CoV-2 infection. Six (75%) instances of presumed noso-
comial transmission, all in preterm babies, occurred 
more than 7 days after birth in babies hospitalised in 
neonatal units (six babies) or PICUs (one baby, who was 
also cared for in a neonatal unit) following preterm birth 
or a congenital condition. Further details of SARS-CoV-2 
testing are presented in appendix 2 (p 5).
Of the 62 babies for whom sex was reported, 27 (44%) 
were male and 35 (56%) were female. 29 (45%) were 
from Black, Asian, or other minority ethnic (BAME) 
groups, an incidence of 11·1 (95% CI 7·4–15·9) compared 
with 4·6 (3·2–6·4) per 10 000 livebirths in babies from 
white ethnic groups (table 1). Although the majority of 
affected babies were born at term, incidence was highest 
in preterm infants (table 1).
The most common signs at presentation were 
hyperthermia and poor feeding or vomiting. Coryza, 
respiratory signs, and lethargy were also commonly 
reported, and seven (11%) infants (all diagnosed in the 
first 7 days after birth) had no reported signs of infection, 
having only been tested following suspected maternal 
infection (figure 3). Hyperthermia, coryzal signs, and 
poor feeding were more commonly reported in babies 
diagnosed with SARS-CoV-2 later than 7 days after birth. 
Of the 25 babies who had a chest x-ray, 14 (56%) had 
abnormal findings, with ground-glass changes reported 
in seven (28%) babies (of whom four were preterm). 
Figure 1: SARS-CoV-2 infection reporting profile
BPSU=British Paediatric Surveillance Unit. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. *There 
were three more cases notified that were not confirmed as SARS-CoV-2 infection in the first 28 days because the 
date of birth or date of diagnosis was missing.
66 cases notified through BPSU system from March 1 to April 30, 2020
4 data collection forms not received
18 duplicates removed
1 excluded (age >28 days)
23 additional non-duplicate cases of confirmed 
SARS-CoV-2 in neonatal period between 
March 1 and April 30, 2020 (test data from 
Public Health England, Public Health Wales, and 
Health Protection Scotland)
62 data collection forms received
44 non-duplicate potential cases
66 cases included in analysis
67 identified cases*
Cases Incidence of SARS-
CoV-2 infection per 
10 000 livebirths 
Total 66 5·6 (4·3–7·1)
Gestational age at birth, weeks 
≥37 48 (73%) 4·9 (3·6–6·5)
32 to <37 14 (21%) 18·4 (9·8–31·4)
28 to <32 1 (2%) 12·1 (0·3–67·0)
<28 1 (2%) 20·2 (0·5–112·5)
Missing data 2 (3%) ··
Ethnicity
White 36 (55%) 4·6 (3·2–6·4)
Asian or Asian British 14 (21%) 15·2 (8·3–25·5)
Black, African, Caribbean, or 
Black British
8 (12%) 18·0 (7·8–35·5)
Mixed or other 7 (11%) 5·6 (2·2–11·5)
Missing data 1 (2%) ··
Severe disease* 28 (42%) 2·4 (1·6–3·4)†
Data are n (%) or incidence (95% CI). SARS-CoV-2=severe acute respiratory 
syndrome coronavirus 2. *Cases meeting at least two of following: (1) any of 
hyperthermia (>37·5°C), apnoea, cough, tachypnoea, respiratory distress or 
recession, supplemental oxygen requirement, poor feeding or vomiting, or 
diarrhoea; (2) any of low white blood cell count, low lymphocyte count, or raised 
C-reactive protein concentration; and (3) abnormal chest x-ray.4 †Incidence of 
severe disease per 10 000 livebirths in the population.
Table 1: Incidence of SARS-CoV-2 infection in March and April, 2020
See Online for appendix 2
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The most common biochemical and haemato logical 
abnormal ities were raised lactate (>2 mmol/L; 17 (55%) 
of 31 babies tested) and raised C-reactive protein (>5 
mg/L; 14 (29%) of 49 babies). Five (9%) of 54 babies 
tested had a low lymphocyte count (<1 × 10⁹/L). Further 
details are provided in appendix 2 (p 5). Eight babies 
underwent cranial ultrasound, and no abnormalities 
were detected.
42 (64%) babies were looked after on a paediatric or 
postnatal ward, 20 (30%) received care in a neonatal unit, 
and four (6%) in a PICU. In total, 22 (33%) babies 
received one or more types of respiratory support: three 
(one born preterm at 36 weeks’ gestation) received 
invasive ventilation, ten (four born preterm at 30, 32, 34, 
and 35 weeks’ gestation) received non-invasive ventilatory 
support, and 22 (five born preterm at 30, 32, 34, 35, and 
36 weeks’ gestation) received supplemental oxygen.
Of the 21 babies who were diagnosed with SARS-CoV-2 
infection within 7 days of birth, 14 (67%) were born at 
term, one (5%) baby (born preterm) was ventilated, 
eight (38%) babies (three born at term) received 
supplemental oxygen, and five (24%) babies (one born at 
term) received non-invasive respiratory support. Overall, 
two (3%) of 66 babies were treated with antiviral agents, 
two (3%) others were treated with corticosteroids, and 
one (2%) other received pooled immunoglobulin 
(table 3).
Median length of stay for babies with SARS-CoV-2 
infection was 2 days (IQR 1–4); those admitted to a 
neonatal unit had a longer median length of stay (7 days 
[2–55]) than those admitted to a PICU or a paediatric 
ward (2 days [0–4]). 58 (88%) babies were discharged 
home, seven (11%) were still inpatients at the time of last 
data collection form submission, and one (2%) died from 
a cause unrelated to SARS-CoV-2.
Discussion 
Using population-level active surveillance data, we con-
firmed that inpatient care for neonates with confirmed 
SARS-CoV-2 is rare, with 5·6 cases per 10 000 livebirths 
(one in 1785) at the UK peak in March and April, 2020. 
Infection in the first 7 days after birth to a mother with 
perinatal SARS-CoV-2 infection was uncommon and 
generally mild or asymptomatic, despite a national policy 
that promoted keeping mother and neonate together. 
We identified only two babies with possible vertically 
acquired infection and six who were suspected of 
contracting SARS-CoV-2 within a neonatal unit or PICU. 
Neonatal SARS-CoV-2 infection led to severe disease in 
42% of cases, and 36% of the babies in this study received 
care in a neonatal unit or PICU. 33% of babies required 
some form of respiratory support. However, this 
requirement might have been related to other conditions, 
such as prematurity, rather than SARS-CoV-2 infection. 
Neonates from Black, Asian, and mixed or other ethnic 
groups accounted for almost half of neonates admitted 
with SARS-CoV-2 infection.
Newborn babies can be affected by SARS-CoV-2 in a 
number of different ways: through infection, following 
vertical or horizontal transmission, and indirectly, 
through maternal COVID-19 (eg, in cases of preterm 
birth caused by maternal disease). The data presented 
here provide evidence on the incidence and outcomes of 
horizontal and possible vertical transmission among 
Figure 2: Date of diagnosis (A) and age at diagnosis (B) of babies diagnosed 
with severe acute respiratory syndrome coronavirus 2 infection from 
March to April, 2020 (n=66)
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Cases (n=66)
Immediate family or close contacts with signs or 
symptoms of COVID-19
Yes 34 (52%)
No 20 (30%)
Unsure 12 (18%)
Mother confirmed to have SARS-CoV-2 infection at birth 17 (26%)
Baby separated from mother immediately after birth 7 (11%)
Not admitted to neonatal care unit 4 (6%)
Admitted to neonatal care unit 3 (5%) 
Baby not separated from mother 8 (12%) 
Separation status not known 2 (3%)  
Possible vertically acquired infection* 2 (3%)
Suspected nosocomially acquired infection† 8 (12%)
Data are n (%). Categories overlap and the potential source of transmission was 
not known or reported in some cases. SARS-CoV-2=severe acute respiratory 
syndrome coronavirus 2. *SARS-CoV-2 isolated from a sample taken from infant 
within 12 h of birth where mother was positive. †Not born to a mother with 
confirmed SARS-CoV-2 infection.
Table 2: Transmission of SARS-CoV-2 to neonates
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neonates who received inpatient hospital care. Previous 
systematic review data describing 666 births following 
maternal SARS-CoV-2 infection identified 28 cases of 
early neonatal infection,17 mainly from case reports, single-
centre case series, and voluntary registries, with a lack of 
clarity about the proportion of ascertained, duplicate, and 
overlapping cases. Representative population-based data 
have so far been limited to that reported through UKOSS,14 
which described 12 infants with confirmed SARS-CoV-2 
infec tion. In this study, we report in greater detail the 
samples, clinical presentation, course, and outcomes for 
17 babies in whom neonatal infection followed maternal 
perinatal infection. The data presented include the SARS-
CoV-2-positive babies reported by UKOSS. We confirmed 
that early neonatal infection is rare and generally mild: 
only four babies born at term with early neonatal SARS-
CoV-2 infection received any respiratory support, and 
none were ventilated. This study took place in the UK, 
where guidance was, and remains, to keep mother and 
baby together when the mother has confirmed perinatal 
SARS-CoV-2 infection.9 Separation of mother and baby 
has multiple detrimental consequences for both mother 
and baby,10,11 and is not recommended by WHO guidance.8 
Over the study period, more than 300 mothers with 
confirmed SARS-CoV-2 infection gave birth,14 and the low 
number of early neonatal SARS-CoV-2 infections and the 
mild disease course we documented support the approach 
taken in the UK. Furthermore, seven babies who were 
separated from their mothers immediately after birth still 
contracted SARS-CoV-2, suggesting that such action 
might not be effective at preventing early neonatal 
transmission. It is unclear why four of these seven babies 
were separated from their mothers, but it might reflect 
evolving local guidance early in the UK pandemic.
There remains considerable uncertainty about vertical 
transmission of SARS-CoV-2. Raised IgM titres in 
neonatal umbilical blood samples following maternal 
perinatal SARS-CoV-2 infection18,19 and detailed case 
reports2,20 support possible vertical transmission, although 
no reports to date meet the criteria for confirmed vertical 
transmission proposed by Shah and colleagues.16 Data 
from UKOSS provide the only available population-
level data to inform the possible incidence of vertical 
transmission: six babies with SARS-CoV-2 isolated within 
the first 12 h. More focused neonatal follow-up through 
the BPSU surveillance system showed that five of these 
six babies were later confirmed to be negative for SARS-
CoV-2, consistent with data from a single-centre study 
indicating that SARS-CoV-2 tests taken immediately after 
birth can have a considerable false positive rate.21 Thus, 
linked population-level obstetric and neonatal active 
surveillance data suggest that vertically transmitted 
neonatal SARS-CoV-2 infection is very rare, even at the 
height of a pandemic. However, this finding must be 
Cases (n=66)
Highest location of care
Neonatal unit 20 (30%)
Paediatric intensive care unit 4 (6%)
Paediatric inpatient ward 30 (45%)
Postnatal ward 12 (18%)
Clinical care received for COVID-19
Invasive ventilation (endotracheal intubation)* 3 (5%)
Non-invasive ventilation* 10 (15%)
Supplemental oxygen* 22 (33%)
High-frequency oscillatory ventilation 0 
Nitric oxide 0 
Extracorporeal membrane oxygenation 0 
No respiratory support 42 (64%)
Therapeutic hypothermia 0 
Missing data 2 (3%)
Treatments received at time of COVID-19
Antibiotics 46 (70%)
Antivirals 2 (3%)
Corticosteroids 2 (3%)
Anti-arrhythmic treatment 1 (2%)†
Immunoglobulin 1 (2%)
Outcome
Still admitted 3 (5%)
Discharged home 58 (88%)
With home oxygen 0
With home respiratory support 0
For palliative care 0
With community nursing 2 (3%)
No additional support 56 (85%)
Transferred to another hospital 4 (6%)
Died 1 (2%)
Missing data 0
Data are n (%). *Some babies received multiple forms of respiratory support. 
†Administered for condition considered unrelated to COVID-19.
Table 3: Treatment and outcomes 
Figure 3: Clinical signs at presentation (n=66)
The number of patients in each category is shown above each bar. Percentages are calculated on non-missing data. 
Missing data: n=1 for apnoea, hypoglycaemia, rash, seizures, and none; n=2 for hypothermia, lethargy, diarrhoea, 
and respiratory distress; and n=3 for coryza, cough, and hypotonia.
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interpreted with caution, for two main reasons. First, our 
pre-specified definition of possible vertically acquired 
infection might have underestimated the true frequency 
because testing of newborn babies within 48 h after 
birth was not recommended in the UK, and thus 
few babies were tested within the first 12 h. Second, the 
proportion of asymptomatic infections is unknown, so it 
is not possible to accurately determine the population of 
SARS-CoV-2-positive mothers necessary to calculate 
incidence. Pregnant women in the UK were asked to 
shield from March, 2020, so their incidence of infection 
was likely to have been lower than that of the general 
population. For these reasons we have not attempted to 
estimate the incidence of possible vertically acquired 
infection. The rarity of such cases is consistent with data 
from three hospitals in New York City (NY, USA), 
in which routine neonatal testing of babies from 
116 mothers with confirmed perinatal SARS-CoV-2 
infection identified no neonatal cases.22
Neonates can also be infected with SARS-CoV-2 outside 
the immediate perinatal period. There are, however, no 
other population-level data describing later-onset neo-
natal infection up to 28 days after birth. The largest 
descriptive cohorts to date were drawn from a multi-
national study that included data from 84 institutions in 
Europe (including 15 in the UK)5 and the UK-based 
ISARIC4C prospective observational cohort study, which 
reported data from Jan 17 to July 3, 2020.23 The European 
registry cohort describes 40 and the ISARIC4C cohort 
53 babies with SARS-CoV-2 infection in the first month 
after birth (some of whom are likely to be a subset of 
our cohort).
Our population-level data confirm that neonates have 
more severe disease than older children: 36% received 
critical care or respiratory support, in contrast to 13% in 
older children;5 42% of neonates met the criteria for 
severe disease, in contrast to 6% of children up to 
18 years of age.4 Although viral respiratory infections in 
neonates24 are associated with an increased requirement 
for respiratory support, critical care or respiratory 
support in some cases might have been related to other 
newborn conditions, such as preterm birth, which was 
also more common among babies with SARS-CoV-2 
infection than among the general population. Crucially, 
although the long-term consequences of early-life SARS-
CoV-2 exposure or infection are as yet unknown, short-
term outcomes were excellent in this cohort: 60% of 
babies were discharged home without the requirement 
for additional support, and there were no deaths 
attributable to SARS-CoV-2 infection. By contrast, poor 
perinatal outcomes were observed during the 2009–10 
H1N1 influenza pandemic.25 We also found that babies 
were more likely to present with poor feeding or vomiting 
or with coryzal signs than were older children23 or adults.1
9% of neonatal SARS-CoV-2 cases followed suspected 
nosocomial transmission within neonatal or PICU 
settings, indicating that such units might need to review 
facilities and procedures for isolation of highly infectious 
cases during this and future pandemics. Further research 
is required to understand the effects of hospital visiting 
restrictions on the nosocomial spread of this and other 
highly transmissible viruses.26
The over-representation of BAME groups in neonatal 
SARS-CoV-2 infection is consistent with patterns 
described in UK maternity,14 paediatric,23 and adult data. 
This finding could be explained by the increased inci-
dence of SARS-CoV-2 infections in March and April in 
areas with higher proportions of BAME groups relative 
to the whole UK, or might be due to other predisposing 
factors in the BAME population, and highlights the need 
for further urgent research in this area. We also 
found that babies born preterm were over-represented 
(24% of babies in this cohort compared with 8% of 
livebirths in England and Wales in 2018). Immune 
function3 differs and susceptibility to a range of 
pathogens is greater in preterm than in term babies;27 
however, the finding that six (38%) of the 16 preterm 
babies had suspected nosocomial infection suggests that 
viral exposure within health-care settings could also 
contribute to the over-representation of preterm babies 
in the SARS-CoV-2 cohort.
The major strength of this study is that it reports UK-
wide, population-level incidence data from a single 
national health service through the use of an established 
active surveillance system,28 with high reporting levels 
by UK paediatricians during the study period. The long-
standing monthly BPSU reporting cards were 
augmented with additional weekly reporting cards for 
this study, and surveillance was further supplemented 
by national virology testing, PICU, and mortality data 
to maximise case ascertainment. The number of babies 
identified through these other sources highlights the 
importance of multiple-source notification and linkage 
during a health crisis. This study was prioritised as an 
urgent public health COVID-19 study in the UK, which 
ensured involve ment of NIHR Clinical Research 
Network staff across paediatric and neonatal units. This 
study was done in conjunction with the national 
surveillance of maternal COVID-19 through the UKOSS 
system in order to facilitate the ascertainment of cases 
of potential vertical transmission and more detailed 
neonatal data describing cases reported by UKOSS.14 
This linked surveillance will also be used to describe 
the indirect effects of maternal SARS-CoV-2 infection 
on neo nates, including babies without confi rmed 
SARS-CoV-2 infection. More detailed data will be 
available through future linkage with data held by 
PICANet13 and the National Neonatal Research 
Database.29 It is important to note that BPSU is the only 
national active surveillance platform in the UK for 
neonatal SARS-CoV-2 infection, and that all other 
reports of babies admitted to hospital with SARS-CoV-2 
infection in the first 28 days in the UK will be subsets 
of these data.
For more on urgent public 
health COVID-19 studies see 
https://www.nihr.ac.uk/covid-
studies/
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Limitations of this study include a focus on essential 
data to limit the reporting burden on paediatricians in the 
setting of a coordinated national health service response 
to the COVID-19 pandemic; therefore, we did not collect 
detailed longitudinal data on physiological status or 
biochemical or haematological test results. Consequently, 
we operationalised the definition of critical or severe 
disease4 as described in table 1. We also did not specify the 
testing to be done and national policy varied over the study 
period, and we were therefore unable to confirm any baby 
infected as a consequence of vertical transmission in line 
with the classification proposed by Shah and colleagues.16 
Additionally, we did not collect longitudinal data describing 
infant feeding and are thus unable to examine the 
relationship between breastfeeding and neonatal SARS-
CoV-2 transmission. Finally, because our aim was to collect 
population-based information about neonatal SARS-CoV-2 
infection in babies receiving inpatient hospital care, this 
study does not provide any data about overall infection 
rates or asymptomatic infection.
Inpatient admission in neonates with SARS-CoV-2 
infection is rare and most babies are only mildly affected 
in the neonatal period. The long-term effects of early-life 
exposure to SARS-CoV-2 are unknown, and ongoing 
data collection, linkage, and follow-up are crucial. 
Furthermore, inpatient admission for neonatal infection 
following birth to a mother with perinatal SARS-CoV-2 
infection was especially uncommon, with only 17 cases 
found across the UK during the study period. Although 
social, economic, and other factors must be incorporated 
in policy decisions, these data support current UK9 and 
international guidance8 to avoid routine separation of 
mother and baby and ensure that new parents can make 
informed decisions about neonatal care.
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